A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

Trial Details

NCT ID
NCT06259552
Phase
PHASE1
Sponsor
SparX Biotech(Jiangsu) Co., Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Males and females ≥18 years of age who comprehend, are not incarcerated, are willing and able to provide consent by signing an ICF, and able to com…
  • Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy
  • Patients who have progressed on or after prior therapy and who are not eligible for available treatment options
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →